Pharmacological Approach of Type 2 Diabetes Mellitus

BMI

Body Mass Index

CKD

Chronic kidney disease

CVD

Cardiovascular disease

DPP

Diabetes Prevention Program

DPP – 4i

Dipeptidyl peptidase - 4 inhibitors

GIP

Glucose dependent insulinotropic polypeptide

GLP-1Ra

Glucagon like peptide – 1 receptor agonists

GRADE

Grading of Recommendations Assessment, Development and Evaluation

HbA1c

Glycated hemoglobin A1c 

HF

Heart failure

MASH

Metabolic dysfunction-associated steatohepatitis

RCT

Randomized controlled trial

SGLT2i

Sodium glucose co transporter 2 inhibitors